SCHEMBL24976102

SCHEMBL24976102

Cc1cc(Cl)c2cc(C=O)ccc2n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
MAPT P10636 5/20 0.51
ALDH1A1 P00352 7/20 0.44
POLB P06746 4/20 0.42
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
PTK2B Q14289 1/20 0.42
CYP1A2 P05177 1/20 0.41
IP6K1 Q92551 2/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
PTGER4 P35408 1/20 0.38
MPI P34949 1/20 0.37
VCAM1 P19320 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30718835 1.00 LMNA (0.62) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL5517317 0.87 MAPT (0.51) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL28910025 0.84 CYP1A2 (0.53) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL14690627 0.83 ALDH1A1 (0.47) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL28910028 0.80 IDO1 (0.44) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL28910006 0.78 ALDH1A1 (0.50) MAPTALDH1A1POLBKDM4ESMN1; SMN2
SCHEMBL30572382 0.77 LMNA (1.00) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL4768081 0.77 LMNA (1.00) LMNAMAPTALDH1A1POLBKDM4E
SCHEMBL10824124 0.77 LMNA (0.72) LMNAMAPTALDH1A1POLBSMN1; SMN2
SCHEMBL3648083 0.77 LMNA (0.72) LMNAMAPTALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
CN-119325469-A WEE1 degrading compounds and uses thereof 百时美施贵宝公司 2025-01-17 CN disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed
WO-2023008577-A1 RAS/RAF BINDING INHIBITOR COMPOUND 国立大学法人神戸大学 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 LMNA 2661/4885MAPT 2871/4885ALDH1A1 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.